Sucralfate
Unchecked
From Pharmacopedia
More actions
Sucralfate
Carafate
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Duodenal ulcer (active treatment and maintenance)0, Stress ulcer prophylaxis0, Radiation-induced oral mucositis (off-label slurry)0, Bile reflux gastritis0
Pharmacy
Starting dose
1 g PO QID on an empty stomach (1 hour before meals and at bedtime); 1 g BID for maintenance
Preparations
1 g tablets; 1 g/10 mL suspension
US FDA Max
4 g/d typical
Pharmacology
Routes
Oral
Onset
Mucosal protection within hours; ulcer healing over 2-4 weeks
Duration
6 hours per dose
Half-life
Not meaningfully described — sucralfate is essentially non-absorbed[1]
Bioavailability
<5% systemic absorption (this is the safety basis)[1]
Pregnancy
Generally considered safe due to minimal systemic absorption.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Sucralfate is a complex of sucrose octasulfate and polyaluminum hydroxide; in the acidic gastric environment it polymerizes into a viscous, sticky gel that selectively binds ulcer crater protein exudates, forming a physical protective barrier over ulcer beds without changing acid secretion.0 Also stimulates local prostaglandin and mucus production. Substantial impact on absorption of co-administered drugs (binds tetracyclines, fluoroquinolones, digoxin, levothyroxine, warfarin) — separate dosing windows by ≥2 hours. Aluminum accumulation in advanced CKD is the systemic-toxicity concern[1].
References
edit- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Carafate (sucralfate), Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019183s050lbl.pdf